Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Montani

Showing results (11-20 of 457) with videos related to

Pageof 46
Sort By:
Chest|June 10, 2011
Predicting survival in pulmonary arterial hypertension: time to combine markersMarc Humbert, David Montani, Rogério Souza
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 1, 2021
Pulmonary hypertension: A rare but severe complication of common variable immunodeficiencyPierre Thoré, Marc Humbert, David Montani
Orphanet Journal of Rare Diseases|July 10, 2025
Cobalamin C deficiency: a rare but treatable genetic cause of pulmonary hypertensionJulien Grynblat, Florence Coulet, David Montani
Circulation|June 3, 2011
Letter by Montani et al regarding article, "Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension"David Montani, Marc Humbert, Rogerio Souza
American Journal of Respiratory and Critical Care Medicine|June 11, 2026
Venular remodeling as an integral component of CTEPH Rather Than a Distinct PathologyDavid Montani, Christian Gerges, Peter Dorfmüller
ERJ Open Research|December 31, 2025
Pulmonary arterial hypertension associated with toxic rapeseed oil: a continuous disease?Julien Grynblat, Charles Khouri, David Montani
ERJ Open Research|February 18, 2026
Pulmonary hypertension associated with COPD: exploring the complex spectrum of an unmet clinical challengeMarianne Riou, Antoine Beurnier, David Montani
Current Opinion in Pulmonary Medicine|June 23, 2017
Pulmonary arterial hypertension induced by tyrosine kinase inhibitorsJason Weatherald, Marie-Camille Chaumais, David Montani
Frontiers in Physiology|April 29, 2021
The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal ModelHélène Le Ribeuz, David Montani, Fabrice Antigny
Chest|May 9, 2024
Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?Léon Genecand, Frédéric Lador, David Montani, et al.
Pageof 46

Showing results (11-20 of 457) with videos related to

Sort By:
Pageof 46
Chest|June 10, 2011
Predicting survival in pulmonary arterial hypertension: time to combine markersMarc Humbert, David Montani, Rogério Souza
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 1, 2021
Pulmonary hypertension: A rare but severe complication of common variable immunodeficiencyPierre Thoré, Marc Humbert, David Montani
Orphanet Journal of Rare Diseases|July 10, 2025
Cobalamin C deficiency: a rare but treatable genetic cause of pulmonary hypertensionJulien Grynblat, Florence Coulet, David Montani
Circulation|June 3, 2011
Letter by Montani et al regarding article, "Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension"David Montani, Marc Humbert, Rogerio Souza
American Journal of Respiratory and Critical Care Medicine|June 11, 2026
Venular remodeling as an integral component of CTEPH Rather Than a Distinct PathologyDavid Montani, Christian Gerges, Peter Dorfmüller
ERJ Open Research|December 31, 2025
Pulmonary arterial hypertension associated with toxic rapeseed oil: a continuous disease?Julien Grynblat, Charles Khouri, David Montani
ERJ Open Research|February 18, 2026
Pulmonary hypertension associated with COPD: exploring the complex spectrum of an unmet clinical challengeMarianne Riou, Antoine Beurnier, David Montani
Current Opinion in Pulmonary Medicine|June 23, 2017
Pulmonary arterial hypertension induced by tyrosine kinase inhibitorsJason Weatherald, Marie-Camille Chaumais, David Montani
Frontiers in Physiology|April 29, 2021
The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal ModelHélène Le Ribeuz, David Montani, Fabrice Antigny
Chest|May 9, 2024
Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?Léon Genecand, Frédéric Lador, David Montani, et al.
Pageof 46